Efficacy of Office-Based Intralesional Steroid Injections in the Management of Subglottic Stenosis: A Systematic Review

xlomafota13 shared this article with you from Inoreader Efficacy of Office-Based Intralesional Steroid Injections in the Management of Subglottic Stenosis: A Systematic Review Via ear nose throat Ear Nose Throat J. 2021 Mar 26:1455613211005119. doi: 10.1177/01455613211005119. Online ahead of print. ABSTRACT OBJECTIVE: To determine the efficacy of office-based intralesional steroid injections (ILSI) as a management therapy for adult subglottic stenosis (SGS). DATA SOURCES: A systematic review was completed using PubMed and Science Direct for office-based management of SGS due to various etiologies. REVIEW METHODS: The primary end point measured was a chang e in surgery free interval (SFI) between endoscopic procedures due to office-based serial ILSI. The secondary end point was to determine what percentage of patients did not require further operative intervention for SGS maintenance therapy after changing management to office-based serial ILSI. RESULTS: We identified 187 abstracts, 4 of which were included in the analysis. The total number of participants was 55. The mean age was 50.4, and 78.1% were women. The etiologies were as follows: idiopathic (58.2%), postintubation/tracheotomy (29.1%), and autoimmune (12.7%). The SFI was reported in 3 of the 4 studies. The reported mean pre-ILSI SFI was 362.9 days and the post-ILSI SFI was 582.2 days. The secondary outcome was reported in 3 of the 4 studies. Forty-one of the 55 patients (74.5%) did not require further operative intervention during the duration of the study. CONCLUSION: This review explored office-based ILSI as a potential treatment option for patients with SGS. Th e limited data presented found ILSI significantly lengthened SFI, potentially reducing surgical burden. In addition, ILSI was found to be safe with few reported side effects. PMID:33765859 | DOI:10.1177/01455613211005119 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.